|
Thrombocytopenia
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
These observations suggest that thrombopoietin is unlikely to have direct effects on other malignant or normal tissue should it have a clinical role in the treatment of chemotherapy-induced thrombocytopenia.
|
7627956 |
1995 |
|
Thrombocytopenia
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Moreover, when recombinant mpl ligand is used in combination with r-metHuG-CSF, both thrombocytopenia and neutropenia can be prevented to the same degree as with either cytokine alone.
|
9372076 |
1996 |
|
Thrombocytopenia
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
Human thrombopoietin levels are high when thrombocytopenia is due to megakaryocyte deficiency and low when due to increased platelet destruction.
|
8639762 |
1996 |
|
Thrombocytopenia
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
To determine plasma thrombopoietin levels in cirrhotic patients with thrombocytopenia, monitor those levels before and after orthotopic liver transplantation, and compare thrombopoietin messenger RNA (mRNA) levels in liver samples from cirrhotic patients and controls.
|
9265428 |
1997 |
|
Thrombocytopenia
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
In patients with cancer who are treated with chemotherapy, the duration of thrombocytopenia was shorter in patients treated with Mpl ligand than in those receiving placebo.
|
9288463 |
1997 |
|
Thrombocytopenia
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
These findings implicate the combination of megakaryocytes and the latter particles as a sink for circulating Tpo in NF-E2 knockout mice, and provide an explanation for the lack of elevated serum Tpo levels in this unique animal model of thrombocytopenia.
|
9292514 |
1997 |
|
Thrombocytopenia
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Recombinant human TPO could be of value in patients developing severe thrombocytopenia under IFN- therapy.
|
9794931 |
1998 |
|
Thrombocytopenia
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
Serum thrombopoietin levels in patients correlate inversely with platelet counts during chemotherapy-induced thrombocytopenia.
|
9529122 |
1998 |
|
Thrombocytopenia
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
We found elevated TPO serum levels in all patients, excluding a TPO production defect as a pathomechanism for the thrombocytopenia.
|
11012189 |
1998 |
|
Thrombocytopenia
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Based on the encouraging results of the initial clinical trials, TPO holds promise as a useful therapeutic agent in the prevention and treatment of thrombocytopenia in cancer patients and other disorders.
|
9685172 |
1998 |
|
Thrombocytopenia
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
We conclude that thrombocytopenia in liver cirrhosis is caused not only by platelet destruction but also by decreased platelet production, perhaps due to reduction of thrombopoietin mRNA in the liver.
|
9794189 |
1998 |
|
Thrombocytopenia
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Feline thrombopoietin (TPO) was molecularly cloned to establish a basis for cytokine therapy of thrombocytopenia in cats. cDNA clones covering the whole coding sequence of feline TPO were isolated from feline liver.
|
9880100 |
1998 |
|
Thrombocytopenia
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Following platelet peak, BALB/c mice developed autoantibodies against murine TPO leading to thrombocytopenia and depletion of megakaryocytes and hemopoietic progenitors in bone marrow.
|
9551904 |
1998 |
|
Thrombocytopenia
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
MGDF may thus have a role in attenuating the thrombocytopenia associated with acute myeloid leukemia (AML) and its therapy.
|
9711904 |
1998 |
|
Thrombocytopenia
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
To investigate the role of an impaired TPO gene expression in the pathogenesis of thrombocytopenia in pediatric patients suffering from liver failure, we measured hepatic TPO mRNA in children with acute or chronic end-stage liver disease undergoing orthotopic liver transplantation.
|
10347116 |
1999 |
|
Thrombocytopenia
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Since thrombopoietin (TPO), a regulator of thrombopoiesis, is produced mainly in the liver, decreased production of TPO may account for thrombocytopenia in liver diseases.
|
11787473 |
2000 |
|
Thrombocytopenia
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Thrombopoietin (TPO), a major cytokine involved in megakaryocytopoiesis/thrombopoiesis, may be effective for treatment of the thrombocytopenia associated with myelodysplastic syndromes (MDS).
|
10742383 |
2000 |
|
Thrombocytopenia
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Studies on TPO and its receptor (c-mpl) have improved the understanding of inherited and acquired thrombocytopenias in childhood.
|
11446655 |
2001 |
|
Thrombocytopenia
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
These data demonstrate a new mechanism for thrombocytopenia in which antibody develops to TPO; because endogenous TPO is produced constitutively, thrombocytopenia ensues.
|
11719360 |
2001 |
|
Thrombocytopenia
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
TPO levels may be regulated not only by platelets but also by megakaryocytes in AA and ITP, and measurement of TPO levels is useful for diagnosing thrombocytopenia and understanding the pathophysiology of thrombocytopenia.
|
12150725 |
2002 |
|
Thrombocytopenia
|
0.100 |
Biomarker
|
phenotype |
LHGDN |
Thrombopoietin (TPO) plays a central role in the pathogenesis of idiopathic thrombocytopenic purpura (ITP), as it does in other immune-mediated thrombocytopenias.
|
11913997 |
2002 |
|
Thrombocytopenia
|
0.100 |
Biomarker
|
phenotype |
LHGDN |
Thus, our results suggest that one mechanism of thrombocytopenia in patients with cGVHD is low TPO production by BM cells.
|
12879435 |
2003 |
|
Thrombocytopenia
|
0.100 |
GeneticVariation
|
phenotype |
LHGDN |
Thrombopoietin is essential for the maintenance of normal hematopoiesis in humans: development of aplastic anemia in patients with congenital amegakaryocytic thrombocytopenia.
|
12799278 |
2003 |
|
Thrombocytopenia
|
0.100 |
Biomarker
|
phenotype |
LHGDN |
Our studies showed that decreased production of platelets by megakaryocytes due to low thrombopoietin concentration could be a possible cause of thrombocytopenia in liver cirrhosis.
|
15239259 |
2004 |
|
Thrombocytopenia
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
Congenital amegakaryocytic thrombocytopenia (CAMT) and thrombocytopenia with absent radii (TAR) share features of isolated thrombocytopenia, reduced or absent marrow megakaryocytes, impaired responsiveness to thrombopoietin (TPO), and high plasma TPO levels.
|
16822462 |
2006 |